Crystal growth and reaction control for pharmaceutical compounds

Eiichi NAKAMURA（Graduate School of Science, The University of Tokyo）

TOWA PHARMACEUTICAL CO., LTD.

Outline of "Drug Discovery Process Innovation"

Outline of "Drug Discovery Process Innovation"
Towa Pharmaceutical Co., Ltd. is pursuing the following research themes by utilizing synthesis technology and controlled crystallization as a platform at Todai COI Center in the University of Tokyo in collaboration with Dr. Eiichi Nakamura (Molecular Technology Innovation Chair Professor, Office of the President and Department of Chemistry, The University of Tokyo), aiming at realization of " Drug Discovery Process Innovation ".

[Research Themes]

1. Establishment of Innovative "Molecules Control Technology" to freely control physical properties (including crystalline form and particle size) of solid drug substances, which are suitable for preparation of various types of the pharmaceutical products by effectively utilizing the state-of-the-art electron microscope at The University of Tokyo.
2. Establishment of "Asymmetric Synthesis Technology" for the development of efficient new synthetic methods Towa will contribute to the establishment of the healthy aged society by establishing these technologies in "All Japan" and developing fundamental technologies necessary for reinforcement of the pharmaceutical drug industry in Japan.

Towa will provide generic drugs with high quality and lower price as “Basic Drug”※ that are manufactured with accumulated original formulation technologies starting from the drug substances. In this way, Towa will contribute to the reduction of burden on the nation, as well as the improvement of medical quality aiming at solving the issues on the proper use of pharmaceutical products, such as "difficult to take" in the medication.

What is "Basic Drug"?

1. Drugs which are therapeutically useful and essential in each therapeutic area.
2. Drugs which are beneficial to the nation (patients) because of easy-to-take and low price, etc.
3. Drugs which are fully developed products with high quality.

WASURE-NAVI-TO for a better dementia and MCI patient care

Shoji TSUJI（The University of Tokyo Hospital）
Atsushi IWATA（The University of Tokyo Hospital）
Eisai Co., Ltd.

Development and Provision of Healthcare Services K

Hiroyuki ARAI（Graduate School of Pharmaceutical Sciences, The University of Tokyo） Habitus Care Inc.

The University of Tokyo, Professor Arai (Pharmaceutical Sciences) COI R&D Partner, and Habitus Care Inc. have been pursuing "sound body and sound spirit life until senior years". We have striven to provide seamless services as business solutions from life care to sick care.

From 2014 to 2016, we have done enourmous work to seek effective means for prevention of type 2 diabetes via the University of Tokyo COI. This would become the primary care base for constructing and providing "primary care specialist" services utilizing IT solutions.

Also, we have been working toward to provide the new healthcare service that will provide personalized advices for health and life in cooperation with each industry leaders (life insurance company, pharmaceutical company, health insurance society, etc.). This service with consent of users conducts comprehensive data acquisition, accumulation and analysis regarding life habits, family history, lifestyle, EMR etc., which has become cornerstones of itself.